Delivering breakthrough technology to transform diagnosis and treatment
Ativa is a privately-held, emerging growth diagnostic company. We are driven to literally change lives. We are working relentlessly to deliver an affordable diagnostic solution that consolidates blood testing to decentralized healthcare settings globally.
With vast in vitro diagnostics experience, our leadership team and Board of Directors has a proven history of successfully developing and commercializing novel point-of-care (POC) diagnostic technologies.
James McNally, Ph.D. – President, CEO and Board Member
Jim has extensive leadership experience in the medical and diagnostic industry, including most recently serving as vice president of Quest Diagnostics’ Products Division, including its POC companies. He has been awarded 12 patents for health care and diagnostic innovations.
David Deetz – Co-founder, CTO, and Board Member
David has previously founded two other medical device companies, one of which completed a successful IPO on NASDAQ and Deloitte identified as one of the fastest-growing medical device companies in the nation. The other was acquired by Danaher/Radiometer as an important part of its POC product line. The author of 11 U.S. patents, David has raised $140 million in private and public capital for his companies.
Barbara Roth – Co-founder, COO, VP Manufacturing
Formerly Vice President of Manufacturing, Diametrics Medical, Manager of Quality and Regulatory Affairs, Johnson & Johnson, Barbara is responsible for team coordination, quality systems, regulatory strategy, clinical studies, ongoing operations, and overall manufacturing operations.
Travis Murphy – CFO
Travis has 30 years of leadership experience in senior financial management roles with emerging growth technology businesses, supporting efforts in raising over $200 million in private and public equity financing. He is experienced in developing long-range strategic plans, operating forecasts, and establishing financial systems and controls.
Non-Employee Board of directors
James B. Stake – Chairman of the Board, formerly EVP 3M, where he led a number of 3M’s healthcare, commercial and industrial units ranging in size from $100 million to $4 billion in the United States and abroad.
Shenghao Shi – Managing Director of Sinopharm Capital, he previously held the position of General Manager for Dentsply International in diagnostics, including C.R. Bard, GE Healthcare and Medtronic, where he was GM for their China operations.
Jiang Zhang – Managing Partner of Ping An Ventures, the investment arm of the largest private insurance company in China where he currently is heading the healthcare investment initiatives of Ping An Insurance Group.
Mark Bagnall – COO of Naia Pharmaceuticals. As former president and CEO of GenturaDx, a Chinese/American molecular diagnostics company, he successfully managed the turnaround and sale of the company to Luminex in 2012.
Contact us to learn more.